First AD

Second AD

Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

Updates in Advanced Renal Cell Carcinoma from The 2022 International Kidney Cancer Symposium

OncLive News Network®

Hans Hammers, MD, PhD, details his strategies for dosing lenvatinib in patients with advanced renal cell carcinoma.

Lenvatinib Dosing Strategies in Frontline Advanced RCC Treatment

Overview of the Frontline Management and Risk Stratification of Advanced Renal Cell Carcinoma (RCC)

Comparing IO/IO and IO/TKI Frontline Treatment in Advanced RCC

Updates from the CLEAR Study on Efficacy of Lenvatinib plus Pembrolizumab in Patients with Advanced RCC

Nivolumab plus Ipilimumab for Frontline Treatment of Advanced RCC: 5-Year Follow-Up from the CheckMate 214 Trial

Managing Adverse Events of IO/IO Frontline Combination Therapies in Advanced RCC Treatment

COSMIC-313: Frontline Triplet Therapy in Advanced RCC

Emerging Data in Non-Clear Cell RCC Treatment

Exciting Investigational Therapies in Advanced RCC